Strategic acquisitions and strong organic growth for Medical Solutions

Summary by AI BETAClose X

Nolato reported third quarter 2026 sales of SEK 2,500 million, a 3% organic increase, while operating profit (EBITA) declined to SEK 254 million with an EBITA margin of 10.2%, and profit after tax was SEK 172 million. The Medical Solutions segment saw a strong 9% organic sales increase to SEK 1,469 million, driven by Drug delivery and In vitro diagnostics, while Engineered Solutions sales were SEK 1,040 million, with a 3% organic decrease and lower operating profit. For the first nine months, sales were SEK 7,311 million, with operating profit at SEK 761 million and a strong financial position maintained.

Disclaimer*

UK 100

Latest directors dealings